Background: The COVID-19 pandemic had a major impact on solid organ transplant recipients. COVID-19 vaccination plays a crucial role in pandemic management.There is limited data on replication-defective viral vectors [ChAdOx1-nCOV (COVISHIELD)] and whole inactivated one BBV-152 (COVAXIN) in kidney transplant recipients (KTRs). This study aims to assess the humoral immune response and adverse effects of these vaccines in KTRs after the first and second doses of vaccination.
Materials And Methods: Anti-SARS-CoV-2 anti-spike antibody titers were measured in 285 KTRs recipients prior to vaccination, 3 weeks ± 3 days after first dose and 3 weeks ± 3 days after second dose of the COVISHIELD (n = 232) and COVAXIN (n = 55) vaccines. Anti-spike antibodies were measured by the chemiluminescence immunoassay method. The primary outcome was seroconversion after two doses of COVAXIN and COVISHIELD and secondary outcome was the incidence of adverse events to COVID-19 vaccines within one week of vaccination.
Results: At baseline, 25 (39.7%) and 67 (30.2%) of KTRs were found to be seropositive before receiving COVAXIN and COVISHIELD, respectively. After first dose of vaccination, 46 (73.0%) and 158 (71.2%) were seropositive and after second dose, 51 (81.0%) and 177 (79.7%) were seropositive, respectively. Common adverse effects were fever, chills, myalgia, and headache which settled in 1-2 days. There was no episode of rejection.
Conclusion: Both ChAdOx1-nCOV and BBV-152 were well tolerated and induced robust antibody formation in KTRs in the Indian population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883331 | PMC |
http://dx.doi.org/10.25259/ijn_549_23 | DOI Listing |
Clin Transplant
March 2025
Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
Background: This study aims to analyze the patient characteristics, clinical outcomes, and contemporary trends concerning type A aortic dissection (TAAD) in previous recipients of abdominal solid organ transplantation (ASOT) in the United States.
Methods: The National Inpatient Sample was queried to identify all patients aged ≥18 with TAAD and a history of ASOT (TAAD-ASOT) between 2002 and 2015Q3 using ICD-9 diagnosis and procedure codes. Baseline characteristics and in-hospital outcomes were compared between TAAD-ASOT patients and TAAD patients without a history of ASOT (TAAD-non-ASOT).
Pediatr Infect Dis J
March 2025
Divisions of Pediatric Emergency Medicine and Pediatric Infectious Diseases, Baylor College of Medicine, Houston, Texas.
Background: Infection is a leading cause of death after pediatric heart transplants (PHTs). Understanding of common pathogens is needed to guide testing strategies and empiric antibiotic use.
Methods: We conducted a 3-center retrospective study of PHT recipients ≤18 years old presenting to cardiology clinics or emergency departments (EDs) from 2010 to 2018 for evaluation of suspected infections within 2 years of transplant.
J Immunol
January 2025
Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Organ transplant recipients require continual immune-suppressive therapies to sustain allograft acceptance. Although medication nonadherence is a major cause of rejection, the mechanisms responsible for graft loss in this clinically relevant context among individuals with preceding graft acceptance remain uncertain. Here, we demonstrate that skin allograft acceptance in mice maintained with clinically relevant immune-suppressive therapies, tacrolimus and mycophenolate, sensitizes hypofunctional PD1hi graft-specific CD8+ T cells.
View Article and Find Full Text PDFBackground: Kidney transplantation (KT) has dramatically improved the quality of life of patients with end-stage kidney disease. However, the incidence of opportunistic infections has also increased because of immunosuppression. A common infection after KT is cytomegalovirus (CMV).
View Article and Find Full Text PDFTransplantation
November 2024
Department of Anaesthesiology and Critical Care, Université de Paris, Hôpital Beaujon, AP-HP, Clichy, France.
Background: Perioperative management practices in liver transplantation (LT) evolve very quickly. There are few specific recommendations, often based on a low level of evidence, resulting in wide heterogeneity of practices.
Methods: We performed a survey in all 16 French centers in 2021 by focusing on center organization, preoperative cardiovascular assessment, antimicrobial prophylaxis, hemostasis management, intraoperative use of hemodynamic monitoring and renal replacement therapy, immunosuppression, and postoperative prevention of arterial complications and compared it with current recommendations.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!